Figure 2.

Progression-free survival (PFS) analysis of sorafenib for human epidermal growth factor receptor 2-negative advanced breast cancer compared with placebo. Total PFS was significantly longer in sorafenib arm (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.56-0.74; p<0.00001). No matter the hormone status is positive or negative, PFS is longer (when treatment) with sorafenib combined with chemotherapy (HR, 0.67, 95% CI, 0.56-0.81, p<0.0001; HR, 0.65, 95% CI, 0.51-0.83, p=0.0005).

IV=inverse variance.